Definition of Relevant Product Market in Reference to R&D Poles in Pharmaceutical Sector Mergers
(2015) JAEM03 20151Department of Law
- Abstract
- All competition analysis, including in relation to mergers, begins by defining the relevant market. In sectors where innovation plays a major role, the definition of the relevant market must also take into account the R&D efforts of the merging firms. One field in which R&D poles can be identified early on is the pharmaceutical sector. In March 2015, the European Commission released the public version of the Novartis/GlaxoSmithKline Oncology Business merger decision, which clarified the market definition process of the Commission regarding R&D poles. The aim of this thesis is to answer the question of how to define relevant product markets concerning R&D poles in pharmaceutical sector mergers. The analysis takes into account the aims of... (More)
- All competition analysis, including in relation to mergers, begins by defining the relevant market. In sectors where innovation plays a major role, the definition of the relevant market must also take into account the R&D efforts of the merging firms. One field in which R&D poles can be identified early on is the pharmaceutical sector. In March 2015, the European Commission released the public version of the Novartis/GlaxoSmithKline Oncology Business merger decision, which clarified the market definition process of the Commission regarding R&D poles. The aim of this thesis is to answer the question of how to define relevant product markets concerning R&D poles in pharmaceutical sector mergers. The analysis takes into account the aims of European Union Competition Law and the possible dangers which may result from different relevant product market definitions. (Less)
Please use this url to cite or link to this publication:
http://lup.lub.lu.se/student-papers/record/7451069
- author
- Karus, Kärt LU
- supervisor
- organization
- course
- JAEM03 20151
- year
- 2015
- type
- H2 - Master's Degree (Two Years)
- subject
- keywords
- R&D, relevant product market, innovation markets, pharmaceutical sector, Merger control
- language
- English
- id
- 7451069
- date added to LUP
- 2015-07-16 15:10:43
- date last changed
- 2015-07-16 15:10:43
@misc{7451069, abstract = {{All competition analysis, including in relation to mergers, begins by defining the relevant market. In sectors where innovation plays a major role, the definition of the relevant market must also take into account the R&D efforts of the merging firms. One field in which R&D poles can be identified early on is the pharmaceutical sector. In March 2015, the European Commission released the public version of the Novartis/GlaxoSmithKline Oncology Business merger decision, which clarified the market definition process of the Commission regarding R&D poles. The aim of this thesis is to answer the question of how to define relevant product markets concerning R&D poles in pharmaceutical sector mergers. The analysis takes into account the aims of European Union Competition Law and the possible dangers which may result from different relevant product market definitions.}}, author = {{Karus, Kärt}}, language = {{eng}}, note = {{Student Paper}}, title = {{Definition of Relevant Product Market in Reference to R&D Poles in Pharmaceutical Sector Mergers}}, year = {{2015}}, }